Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The Gauss/Cellex rapid at-home COVID-19 test. Credit: Gauss

Gauss, a computer vision startup, and Cellex, a biotech company that works on diagnostics, are announcing the first rapid COVID-19 test that can be fully performed by people at home without involving a laboratory.

Why it matters: Experts agree that the U.S. still needs far more widespread testing to help contain the coronavirus pandemic. An antigen test that could be performed and provide results rapidly at home could help reduce testing delays and allow people to quickly find out whether they need to isolate because of a COVID-19 infection.

How it works: In the antigen test, which was developed by Cellex, a user will take a nasal swab to both nostrils, and then place the swab in a small vial filled with a buffer solution.

  • Four droplets from the tube are placed on a rapid test cassette, and test lines will show up of varying intensity, based on whether and how much virus is in the sample.
  • Users will then take a picture of the rapid test, and Gauss's app will use AI to deliver back the results — all within 15 minutes.

Of note: While other rapid diagnostics have been developed that allow users to test themselves at home, those earlier methods still required people to send in samples to a lab or health facility for processing.

  • The Gauss/Cellex diagnostic would be the first test that can be done to completion at home.
  • Cellex CEO James Li says the test demonstrates nearly 90% sensitivity — how often a test generates a correct positive result — compared to PCR tests, and nearly 100% specificity, or how often it produces a correct negative result.
What is important for COVID-19 pandemic management is that this is a tool that will allow people to self-monitor and self-isolate.
— James Li

What to watch: Whether the FDA gives the new test an Emergency Use Authorization, which would allow it to more rapidly come to market.

  • There's also the question of price, although Li says that "our goal is to make this assay as widely available as possible."

The bottom line: Quick and easy at-home tests would certainly help reduce the spread of COVID-19, and they show how the pandemic has accelerated the coming of distributed medicine.

Go deeper

Dec 25, 2020 - World

Chile becomes first South American country to start COVID vaccination

Nurse receiving the Pfizer-BioNTech vaccine in Santiago, Chile. Photo: David Lillo/Ministerio de Salud de Chile via Getty Images

Chile became the first country in South America to begin coronavirus vaccinations on Thursday after receiving its first 10,000 Pfizer-BioNTech doses, Reuters reports.

The big picture: The country bought 10 million doses from Pfizer-BioNTech and is expected to receive 240,000 doses in January, per Reuters.

Dec 25, 2020 - Health

Scientists suspect compound in allergic reactions to Pfizer vaccine

Photo: Mario Tama/Getty Images

Scientists believe the compound polyethylene glycol — known as PEG — is to blame for the reported allergic reactions to the Pfizer-BioNTech coronavirus vaccine, the Wall Street Journal reports.

Driving the news: The Centers for Disease Control and Prevention identified six allergic reactions to the vaccine out of the 272,001 doses given through Dec. 19.

Moderna says vaccine appears to protect against new COVID-19 variants

Photo: Justin Tallis/AFP via Getty Images

Moderna's COVID-19 vaccine is effective against new variants of the virus that first appeared in the U.K. and in South Africa, the company announced on Monday.

Yes, but: The vaccine was as effective against the strain from U.K., but saw a six-fold reduction in antibodies against the South Africa variant. Even still, the neutralizing antibodies generated by the vaccine "remain above levels that are expected to be protective," according to the company.